Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022031605 - COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1

Publication Number WO/2022/031605
Publication Date 10.02.2022
International Application No. PCT/US2021/044192
International Filing Date 02.08.2021
IPC
A61K 31/506 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/4178 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/336 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4168 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4168having a nitrogen atom attached in position 2, e.g. clonidine
A61K 31/473 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
473ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
CPC
A61K 31/336
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
336having three-membered rings, e.g. oxirane, fumagillin
A61K 31/4168
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4168having a nitrogen attached in position 2, e.g. clonidine
A61K 31/4178
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4178not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/473
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
473ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • NEL, Andre E.
  • MENG, Huan
  • LIU, Xiangsheng
Agents
  • HUNTER, Tom
  • WEAVER, Jeffrey K.
  • AUSTIN, James E.
  • VILLENEUVE, Joseph M.
  • SAMPSON, Roger S.
  • GRIFFITH, John F.
  • BERGIN, Denise S.
  • SCHOLZ, Christian D.
  • CHANG, Ko-Fang
  • MARTINEZ-LEMKE, Sheila
  • MCMILLAN, Scott L.
  • SANI, Babak
  • SANI, Barmak S.
  • TSAI, Patricia
  • TSE, Michael
Priority Data
62/706,30807.08.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMBINATION CHEMO-IMMUNOTHERAPY FOR PANCREATIC CANCER USING THE IMMUNOGENIC EFFECTS OF AN IRINOTECAN SILICASOME NANOCARRIER PLUS ANTI-PD-1
(FR) COMBINAISON CHIMIOTHÉRAPIE-IMMUNOTHÉRAPIE POUR LE CANCER DU PANCRÉAS AU MOYEN D'EFFETS IMMUNOGÈNES D'UN NANOSUPPORT SILICASOME D'IRINOTÉCAN ET D'UN ANTICORPS ANTI-PD -1
Abstract
(EN) In various embodiments, methods of treating a cancer are provided. In certain embodiments, the methods comprise administering to a mammal in need thereof i) one or more checkpoint inhibitor(s); and ii) one or more camptothecin analogs, and, optionally, or one or more autophagy inhibitors wherein said camptothecin analog, and one or more autophagy inhibitors, when present, are provided inside a delivery vehicle where said delivery vehicle comprises: a nanoparticle comprising one or more cavities disposed within said nanoparticle and an outside surface where said one or more cavities are in fluid communication the outside surface of said nanoparticle; said one or more camptothecin analog, one or more autophagy inhibitors, when present, are disposed within said one or more cavities; and a lipid bilayer is disposed on the surface of said nanoparticle where said lipid bilayer fully encapsulates the nanoparticle.
(FR) Selon divers modes de réalisation, la présente invention concerne des procédés de traitement du cancer. Selon certains modes de réalisation, les procédés comprennent l'administration à un mammifère en ayant besoin i) d'au moins uninhibiteur de point de contrôle; et ii) d'au moins un analogue de la camptothécine, et, éventuellement, ou au moins un inhibiteur de l'autophagie, ledit au moins un analogue de camptothécine, et ledit au moins un inhibiteur de l'autophagie, lorsqu'ils sont présents, étant disposés à l'intérieur d'un véhicule de distribution, ledit véhicule de distribution comprenant: une nanoparticule comportant au moins une cavité disposée à l'intérieur de ladite nanoparticule et une surface extérieure, ladite au moins une cavité étant en communication fluidique avec la surface extérieure de ladite nanoparticule; ledit au moins un analogue de camptothécine, ledit au moins un inhibiteur(s) de l'autophagie, lorsqu'il sont présents, étant disposés à l'intérieur de ladite au moins une cavité; et une bicouche lipidique étant disposée sur la surface de ladite nanoparticule, ladite bicouche lipidique encapsulant entièrement la nanoparticule.
Latest bibliographic data on file with the International Bureau